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1. Introduction
Unknown primary malignancies (UPMs) are histologically 
proven tumor metastases that lack evidence of a primary 
site. The early and rapid distribution of the disease, the 
clinical failure of the primary tumor diagnosis, and 
unexpected metastatic sites are the main features of UPM. 
Between 5% and 10% of all cancer patients are diagnosed 
with UPM; it is the tenth most frequent cancer and the 
fourth most common cause of cancer-related death (1,2). 
Despite the recent advances in diagnostic techniques, the 
diagnosis and treatment of patients with carcinoma of 
unknown primary origin remains a challenge in practice. 
Conventional imaging modalities may detect the site 
of the primary tumor in only 10%–35% of all cases. A 
histopathological analysis or even an autopsy examination 
may not identify a primary lesion (1–4). In this patient 
population, the diagnosis of the primary tumor site is 
often time consuming, costly, and complex. The low rate 
of detection of the primary cancer is attributed to the size 
of lesions, which are smaller than the spatial and contrast 
resolution of the techniques used for diagnosis, or to the 
involution of the primary mass due to limited angiogenic 
competence (5,6). Early and accurate diagnosis of the 
primary lesion dramatically changes survival of UPM 
patients. The median survival time for patients with UPM 
is short, almost 8 to 12 months; thus, the determination 
of the exact location of the tumor and prompt initiation 
of treatment can extend survival up to 23 months (3,7,8). 
Recently, whole body 18F-FDG PET/ CT hybrid imaging 
has gained wide application in the diagnosis and follow-up 
of cancer patients. 18F-FDG PET can accurately detect the 
primary lesion in 24%–53% of patients whose diagnoses 
were negative based on conventional diagnostic procedures 
(7,9–11). Initial studies of the diagnostic effect of 18F-FDG 
PET/CT in UPM patients have revealed promising results. 
The aim of this study was to evaluate the role of 18F-FDG 
PET/CT imaging in the detection of unknown primary 
tumor sites in patients with a suspicion of malignancy. We 
also intend to supplement the literature with the results of 
our experience.
Background/aim: This study aimed to retrospectively evaluate the role of 18F-FDG PET/CT imaging in the detection of unknown 
primary tumor sites in patients with a suspicious malignancy.
Materials and methods: We retrospectively examined the 18F-FDG PET/CT images of 50 unknown primary malignancy patients. The 
malignancy of the lesions with increased 18F-FDG uptake on PET images was defined by interpreting the nondiagnostic CT images that 
were obtained with the PET study. The primary tumor site was decided according to the combined PET/CT findings, and the results 
were subsequently confirmed with a histopathological examination. 
Results: Fifty patients (29 M; 21 F) aged 18–85 years were included in the study. The sample included 32 malignant and 18 benign lesions 
according to the histopathological evaluation. 18F-FDG PET/CT study accurately identified malignant lesions in 28 (average SUVmax 
± SD: 8.27 ± 7.22) and benign lesions in 12 (average SUVmax ± SD: 3.63 ± 3.07) patients; these findings were histopathologically 
confirmed. PET/CT correctly detected the primary tumor site in 16 (50%) of 32 patients.
Conclusion: 18F-FDG-PET/CT identified the primary tumor site well in 50% of our cases. We propose that 18F-FDG PET/CT imaging 
may help to accurately detect malignant lesions in patients with unknown primary tumors.
Key words: Fluor-18 fluorodeoxyglucose, positron emission tomography/computerized tomography, unknown primary tumor, 
unknown malignancy, hypermetabolic lesions
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2. Materials and methods
We retrospectively examined 18F-FDG PET/CT images of 
82 consecutive patients with UPM whose test results were 
negative for conventional diagnostic procedures, including 
CT, MRI, mammography, and endoscopy. Despite the 
completion of comprehensive laboratory analyses for 
all patients, the primary site of malignancy could not be 
identified. A primary malignancy or at least one metastatic 
site or pathological lesion was histologically proven in only 
50 patients. We analyzed only these 50 patients because the 
histopathological findings were used as the gold standard 
to evaluate the PET/CT results. The institution’s Medical 
Ethics Review Committee approved the study protocol, 
and all patients provided written informed consent prior 
to the PET/CT imaging. A complete medical history and 
physical examination were performed for all patients. 
None of the patients had a history of cancer or received 
chemotherapy and/or radiation therapy prior to the 
18F-FDG PET/CT examination. 
2.1. 18F-flurodeoxyglucose PET/CT
Dual-modality PET/CT was performed using a Gemini 
TF TOF PET/CT scanner (Philips Medical Systems, 
USA). All of the subjects fasted for at least 6 h prior to 
imaging. The fasting blood glucose levels were measured 
prior to the F-18 FDG injection, and patients with glucose 
levels lower than 160 mg/dL received an intravenous 
injection of 3.7 MBq/kg 18F-FDG. PET/CT scanning was 
performed 60 min after the injection of 18F-FDG. Whole-
body CT was performed using a 16-slice helical CT. The 
CT scan data were collected at 50–120 mAs and 90–140 
kV and were adjusted to the patient’s body weight. No 
intravenous or oral contrast material was used. After the 
CT scan, an emission scan was obtained from the head to 
the feet at a rate of 20–60 s per frame. The attenuation-
corrected PET images with CT data were reconstructed 
using an ordered subset expected maximization (OSEM) 
algorithm (33 subsets, 3 iterations). Commercial software 
(Extended Brilliance Workspace, Philips Medical Systems) 
was used to accurately coregister the CT and PET scan 
data. The maximum standard uptake values (SUVmax) 
were calculated using the attenuation-corrected images, 
the amount of injected 18F-FDG, the body weight of each 
patient, and the cross-calibration factors between the PET 
and the dose calibrator. Two experienced nuclear medicine 
physicians retrospectively visually and semiquantitatively 
reviewed the PET, noncontrast CT, and fused PET/CT 
images to locate the primary tumor. The nuclear medicine 
physicians were informed about the clinical background 
of patients, but were blinded to the results of the other 
conventional imaging procedures. The two physicians 
reached a consensus for all of the PET/CT results. On the 
PET images, the primary tumor assessment was based 
on the detection of focally increased glucose (18F-FDG) 
metabolism with a SUVmax exceeding 2.5, whereas an 
enhanced mass or lymph node was the criterion for 
malignancy on nondiagnostic CT images. However, 
malignancy was not solely based on hypermetabolic 
18F-FDG findings; these lesions were also classified as 
malignant by evaluating the entire medical history, 
conducting a physical examination, conducting laboratory 
analysis of the patients, and correlating the nondiagnostic 
CT images that were simultaneously obtained with a 
PET study. The probable site of the primary tumor was 
identified based on the combined findings of PET and CT. 
All potential sites of the primary tumor described by PET/
CT were subsequently confirmed by histopathological 
examinations. The rate of primary tumor detection 
was determined based on comparing the PET/CT and 
histopathological results. Ultimately, true and false positive 
as well as true and false negative findings were defined 
based on the histopathological results (Table 1). The 
diagnosis of malignancy by 18F-FDG PET/CT, irrespective 
of known or unknown primary focus, was classified as true 
positive when it was proven to be a malignant lesion by 
histopathological evaluation.
3. Results
The 50 patients were aged 18–85 years (average ± SD: 
61.64 ± 16.26 years); 29 were male and 21 were female. 
The clinical and histopathological data and the 18F-FDG-
PET/CT findings are reported in Table 1 according to the 
site of the primary tumor. The lesion localizations of 50 
patients on 18F-FDG PET/CT were evaluated (Table 2). The 
histopathological evaluation of all 50 patients identified 32 
malignant and 18 benign lesions. The 18F-FDG PET/CT 
accurately depicted the lesions as malignant or metastatic 
(Figure 1) in 28/32 (87%) patients (average SUVmax ± SD: 
8.27 ± 7.22) compared with the histopathological findings. 
The PET/CT correctly detected the primary tumor site in 
16 (50%) of 32 patients: in the lungs in three cases (# 6, 
14, and 23); the lymph nodes (lymphoma) (#15 and 31), 
liver (# 12 and 22), stomach (# 5 and 20), and colon (# 
4 and 21) in two cases; and the ovary (# 44), cerebrum 
(# 19), soft tissue (ganglioneuroma) (# 42), kidney (# 
3), and endometrium (#30) in one case. However, PET/
CT failed to identify the primary tumor site in 12 of the 
32 patients (37.5%): the colon (Figure 2) in four cases 
(# 17, 18, 39, and 49); the stomach (# 10 and 50), skin 
malignancy (# 8 and 35), and malignant epithelial tumor 
of unknown origin in two cases (# 36 and 37); and the soft 
tissue malignancy (# 40) and a neuroendocrine tumor in 
one case (# 38). In the remaining 4 of the 32 patients who 
were histopathologically diagnosed as having a malignant 
lesion, PET/CT could not identify the malignant lesion or 
metastases (12.5%).  Thus, our PET/CT results yielded a 
false negative in 4 patients (average SUVmax ± SD: 0.95 ± 
1.10) (liver, lung, colon, and soft tissue in patient # 24, 28, 
29, and 41, respectively).
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Table 1. Details of the FDG PET/CT findings in the search for a primary (n = 50 patients).
No Sex Age Histopathology PET/CT Results
1 M 46 Inflammation Benign infectious nodule TN
2 M 83 Infection Infection and inflammation TN
3 F 78 Renal cell cancer Primary renal tumor TP
4 M 73 Colon cancer (low differentiated) Liver met lesions of colon cancer TP
5 M 60 Gastric ca. (Sarcoma met.) Gastric tumor TP
6 M 67 Epithelial lung ca. Malign lung tumor TP
7 M 49 Benign lesion Benign lesion TN
8 F 60 Squamous cell ca. (skin) Met. lesion of UPM TP
9 M 40 Benign lesion Benign TN
10 F 73 met lesion of gastric ca. Met.lesion of UPM TP
11 F 45 Inflammation Benign lesion TN
12 F 38 Hepatocellular ca. Primary liver tumor TP
13 M 54 benign Osteodegenerative  findings TN
14 M 66 Malign epithelial lung tumor Primary lung tumor TP
15 F 73 Lymphoma (NHL) Lymphoma TP
16 M 64 inflammation Met. LNs of UPM TN
17 M 53 Colon adeno ca. met. Met. lesion of UPM TP
18 F 66 Met. lesion (low differentiated colon tumor) Met. lesion of UPM TP
19 M 29 Glioblastoma Primary brain tumor TP
20 F 43 Gastric adeno ca. Primary gastric tumor TP
21 M 83 Met. of low differentiated colon tumor Rectal tumor TP
22 M 79 Hepatocellular ca. Liver tumor and met LNs TP
23 M 85 Lung adeno ca. Primary lung tumor TP
24 M 74 Met. of hepatocellular ca Benign lesions FN
25 F 18 Infection infection TN
26 F 77 Infection Infection TN
27 F 66 Benign lesions Osteodegenerative findings TN
28 F 47 Adeno ca. met (colon or lung) Infection FN
29 M 71 Colon adeno ca. met. Infection FN
30 F 74 Endometrium adeno ca. Endometrium tumor TP
31 M 69 Hodgkin disease Lymphoma TP
32 M 77 inflammation Met. of UPM FP
33 F 57 İnfectious disease Malign disease FP
34 M 51 İnfectious disease Malign disease FP
35 M 57 Met. lesion of squamous cell ca. (skin) Met. lesion of UPM TP
36 M 73 Malign epithelial tumor met. Met. lesion of UPM TP
37 F 79 Malign epithelial tumor met. Met. lesion of UPM TP
38 M 76 Neuroendocrine ca. met. Met. lesion of UPM TP
39 M 59 Colon adeno ca. met. Met. lesion of UPM TP
40 F 83 Soft tissue tumor met. Met. lesion of UPM TP
41 M 64 Liposarcoma Benign infectious lesion FN
42 M 18 Ganglioneuroma Ganglioneuroma TP
43 F 72 Benign lesion Osteodegenerative TN
44 F 56 Over ca. Primary over ca. and met. lesions TP
45 F 75 İnfectious disease Lung malignancy FP
46 M 42 Inflammation Met. lesion FP
47 F 53 Benign disease Benign disease TN
48 F 70 Inflammation Malign disease FP
49 M 51  met of  colon adeno ca. Met. lesion of UPM TP
50 F 66 Gastric ca. met Met. lesion of UPM TP
F: female;  M: male; TP: true positive; TN: true negative; FP: false positive; FN: false negative; met.: metastasis; LN: lymph node; UPM: unknown primary 
tumor;  ca.: cancer.
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The 18F-FDG PET/CT accurately depicted lesions 
as benign (Figure 3) in 12 (67%) of 18 patients, with 
histopathological confirmation. In these 18 patients 
diagnosed with a benign lesion and the 12 true negative 
patients, the average SUVmax ± SD values were 3.95 ± 2.65 
and 3.63 ± 3.07, respectively. In 6 of these 18 patients whose 
average SUVmax ± SD value was 4.52 ± 1.38, the PET/CT 
results yielded a false positive due to benign infectious and 
inflammatory cytomorphology (patient numbers are 32, 
33, 34, 45, 46, and 48) based on histopathology (33%). 
4. Discussion
Unknown primary malignancies include a heterogeneous 
group of malignant tumors that are generally accompanied 
by metastases. The clinical features of patients may 
widely vary and include enlarged lymph nodes anywhere 
in the body, hepatosplenomegaly, bone pain, or fever 
of unknown origin (1,2,12,13). Efforts to detect the 
primary tumor with conventional imaging methods 
in patients with UPM are often unsuccessful. This low 
success of detection prevents the initiation of effective 
Table 2. The patient numbers of malignant and benign results of the PET/CT and histopathological confirmation methods.
Histopathological evaluation Malignant Benign Total
PET/CT evaluation 
Malignant 28 12 40
Benign 4 6 10
Total 32 18 50
Figure 1. 18F-FDG PET/CT transverse images of a 43-year-old woman (Patient number 20) with an unknown primary tumor. PET (A), 
CT (B), fusion (C), and MIP (D) images depict the primary tumor at the lesser curvature of the stomach with increased FDG uptake 
(SUVmax= 4.51), which was later confirmed at histopathologic examination as gastric adenocarcinoma. 
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treatment, which depends on tumor localization and 
differentiation. Although unknown primary malignancies 
are characterized by a poor prognosis, the identification of 
the primary tumor permits the initiation of more specific 
and effective treatments that improve survival. Therefore, 
the detection of the primary lesion significantly changes 
the prognosis and improves survival (10,14,15). In this 
study, 18F-FDG PET/CT was able to conclusively identify 
16 tumor sites among 32 primary malignant lesions, 
and these findings were confirmed by histopathological 
evaluation, which is accepted as the gold standard test. 
However, the detection rates reported in the literature 
significantly vary (24%–59%) (6–8,10,13,16–23). 
We herein report a relatively higher rate of detection 
(50%) of the primary tumor origin by 18F-FDG PET/
CT imaging as compared with many previous studies, 
which reported detection rates ranging from 24% to 
45% (6,8,10,13,16,17,21–23). However, other previously 
published studies reported a similar rate of detection of 
the primary tumor origin (53%–59%) by 18F-FDG PET/
CT imaging (7,18–20). Another published article reported 
a significantly higher detection rate (73%) of the primary 
tumor origin by 18F-FDG PET/CT as compared with our 
results and with those of other studies (24). This higher 
rate may be due to insufficient diagnostic work-up (such 
as medical history, physical examination, full blood count, 
blood biochemistry analysis, and conventional imaging 
methods). The results of another previously published 
systematic review and metaanalysis indicate that FDG-
PET/CT study can detect 37% of primary tumors in 
patients with unknown primary tumors, which constitutes 
a rate lower than our detection rate (12). However, the 
results from the subgroup analysis may not be precise 
because of the small number of included studies. 
Figure 2. 18F-FDG PET/CT images of a 53-year-old man (Patient number 17) who presented with multiple liver lesions. Transaxial 
PET (A), CT (B), fusion (C), and MIP (D) images demonstrate multiple hypodense lesions with pathologically increased FDG uptake 
(SUVmax = 17.84) in the liver and pathologically enlarged, hypermetabolic portal–precaval lymph nodes (SUVmax = 14.70). An 
excisional biopsy of the lesions and subsequent histopathological examination indicated metastatic colon adenocarcinoma. 
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As a result of FDG being both captured and retained 
within metabolically active cells, 18F-FDG can be used 
to determine the high glycolytic activity of various 
malignancies and imaging of these pathological lesions, 
such as malignant melanoma, lung cancer, breast cancer, 
gastrointestinal tract cancers, and genitourinary cancers, 
can be provided by PET/CT. In our study, 18F-FDG PET/
CT correctly identified the primary tumor site in several 
organs in 16 of 32 patients. In many other studies, the 
most common site of the primary tumor was the lung 
(4,8,12,18,21,22,25–27). However, we cannot directly 
identify the most common localization site for the primary 
tumor based on FDG PET/CT because the primary tumor 
regions were heterogeneous in this study. However, the 
most frequent primary tumor focus in our study was the 
lung (three patients), followed by the liver, colon, and 
lymph nodes (two patients each). 
Despite the high detection rate of malignancies by 
18F-FDG PET/CT imaging, the 18F-FDG PET/CT may 
not be able to detect final diagnosis of the primary site for 
various types of neoplasms (6,16). In our study, 18F-FDG 
PET/CT failed to identify the primary tumor site in 12 
of 32 patients with histopathological findings; patients 
had multiple organ metastases, and the malignancy 
could not be identified in 4 patients with a malignant 
histopathological diagnosis. The SUVmax values in the 
lesions were low (<2.10) in these 4 patients. As known, 
18F-FDG uptake can be influenced by tumor grading. High-
grade tumors show elevated glucose consumption with 
high FDG uptake, while uptake can be lower or absent in 
low-grade tumors. In addition, some slow growing tumors 
can metastasize, while some invasive tumors cannot grow 
beyond 1–2 mm in size and thus remain subclinical (5,6). 
Therefore, it is reported that the primary tumor remains 
Figure 3. 18F-FDG PET/CT transverse images of an 83-year-old man (Patient number 2) who presented with an unknown primary 
tumor. PET (A), CT (B), fusion (C), and MIP (D) images show pulmonary nodules in the upper lobes of both the right and left lungs 
with mild FDG uptake (SUVmax = 2.19), which was interpreted as a pulmonary infection. After PET/CT, a bronchoscopic biopsy was 
performed and a subsequent histopathological examination confirmed the F-18 FDG PET/CT diagnosis by showing only infectious 
findings in the specimens.
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unidentified after autopsy in almost 70% of UPM cases 
(1,2,4). Moreover, the primary lesion site is an important 
factor for tumor identification with PET/CT. 18F-FDG is 
not an optimal radiopharmaceutical for certain anatomical 
locations that physiologically accumulate FDG. FDG 
is well known to be physiologically accumulated in the 
muscular, gastrointestinal, renal excretory systems, the 
brain, and especially in inflammatory lesions. These 
accumulation areas lead to uncertainty in the classification 
of lesions (1,3,28). Hany et al. showed that 21% of all 
lesions could not be specified with PET alone, and an 
additional 7% of all lesions could be specifically classified 
via the use of low-dose CT for image coregistration as a 
result of a change in localization (29). Our 4 patients 
with false negative results had a colon adenocarcinoma, 
intraabdominal liposarcoma, lung adenocarcinoma, and 
hepatocellular carcinoma, respectively. We think that our 
false negative findings may be attributed to decreased 
glucose consumption in the tumor tissues and/or their 
inappropriate anatomical locations. 
Some studies have revealed that 18F-FDG PET alone and 
PET/CT imaging yielded similar results in the detection of 
primary tumors of unknown origin (11,13). The efficiency 
of FDG-PET for the detection of an UPM has been assessed 
in a multicenter study of 208 patients, and 18F-FDG PET 
detected a primary tumor in 24%–53% of the patients (11). 
However, recent clinical studies that also aimed to identify 
the primary lesion in UPM patients, similar to us, generally 
relied on the use of hybrid PET/CT equipment instead of 
PET alone. The hybrid system seems to be more accurate 
than PET alone in assessing the presence and location 
of tumoral lesions because it permits the simultaneous 
acquisition of accurately aligned whole body anatomical 
and functional images. Especially, PET/CT imaging is 
significantly superior to PET alone in tumor staging. PET/
CT imaging can improve tumor staging by identifying 
more lesions than conventional imaging methods 
(6,29,30). Thus, FDG PET/CT is a very suitable technique 
to identify a prognosis because the prognosis depends on 
the accurate staging of the disease and the selection of the 
most appropriate treatment approaches (22). PET/CT can 
also direct a biopsy of the primary tumoral lesion and avoid 
other unnecessary invasive investigations. In our study, the 
detection of possible primary tumor locations guided the 
biopsy, and the treatment was modified and adapted to 
the location of the tumor in 16 patients based on 18F-FDG 
PET/CT results alone. 
Moreover, some situations may negatively affect the 
identification of the primary tumor site with the FDG 
PET/CT technique. 18F-FDG is not an optimal tracer for 
inflammatory and infectious processes. False positive 
results may be due to FDG uptake in benign conditions that 
feature increased glycolysis (e.g., pulmonary infarction) 
or high physiological FDG uptake (e.g., muscle FDG 
uptake) (10,12). These conditions may simulate cancer 
and create false positive results. If the 18F-FDG PET/CT 
findings indicate a malignancy, confirmatory invasive 
diagnostic investigations, such as a biopsy, are necessary 
because of the risk for false positivity (31). In our study, the 
PET/CT results were false positive in 6 of 18 (33%) cases 
with histopathologically proven benign disease (benign 
infectious and inflammatory cytomorphology). These 
infectious and inflammatory processes were mostly located 
in the lung (in 4 of 6). The false positive rates in other similar 
studies varied widely from 5.5% to 66.6% (8,10,13,16,22). 
Similar to our findings, the lung has been reported as one 
of two main locations in which false-positive FDG PET/
CT results are highest in patients with UPM. The second 
main location is the oropharynx (12,25). The physiological 
FDG uptake in this location may be misinterpreted as a 
malignant lesion. False positive FDG-PET findings expose 
the patient to advanced invasive diagnostic evaluations 
(laryngoscopies and endoscopies), which incur associated 
costs and morbidities. Therefore, talking, swallowing, and 
chewing should be avoided in patients instantly before and 
after FDG injection to decrease FDG levels in the muscles 
of the larynx and pharynx (12,32). We strictly applied 
these rules, and did not record false positive lesions in the 
oropharyngeal or laryngeal region in any of the patients. 
Previous studies indicated that both attenuation-corrected 
and nonattenuation-corrected images need to be evaluated 
to minimize the chance of misinterpreting artifacts as 
malignant lesions (10,12,16,33). 
Our study showed that 18F-FDG PET/CT accurately 
depicted the malignant lesions in 28/32 patients whose 
lesions were not identified by conventional tests, but were 
histopathologically confirmed. Our results corroborate a 
retrospective study that reported 26 true positive results for 
33 patients (20). Our high sensitivity of 87% indicates that 
18F-FDG PET/CT can effectively identify malignancies. 
18F-FDG PET/CT is superior to conventional diagnostic 
techniques, which could not identify the origin of the 
primary malignancy in our patient group. The superior 
performance of our PET/CT results as compared with 
conventional imaging methods is attributed to the 
whole-body PET/CT images that were analyzed by the 
same experienced nuclear medicine physicians, while 
conventional imaging methods were performed in 
different and specific locations and the images were not 
analyzed by the same radiologist. Our results support the 
advantage of metabolic information over conventional 
imaging methods in the search for a malignancy. We also 
found that PET/CT can change the staging of the disease 
by showing more lesions and more advanced disease than 
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conventional imaging methods. It can also direct a biopsy 
of the primary tumor (Figure 1) and avoid other invasive 
procedures. Irrespective of its capability to detect an 
unknown primary tumor, F-18 FDG PET/CT can detect or 
rule out other possible metastatic sites, which is important 
for patient therapeutic management and prognosis. We 
think that 18F-FDG PET/CT is useful and highly sensitive 
for the diagnostic work-up of patients with metastases of 
unknown origin and can help explore the whole body in 
a single and noninvasive examination. Furthermore, our 
study is novel and more reliable and accurate than other 
studies on the same topic that enrolled UPM patients 
with different selection criteria, such as the exclusion of 
cases with highly suspected clinical findings based on the 
diagnostic work-up or the inclusion of cases with highly 
suspected, but not histopathologically proven, malignant 
or metastatic lesions. 
18F-FDG PET/CT identified the primary tumor site well 
in 50% of our cases. Although validation is required with a 
larger population, the present study indicates that 18F-FDG 
PET/CT may help to accurately determine the lesion site 
in patients with unknown primary tumors. However, 
appropriate use and interpretation of 18F-FDG PET/CT 
are necessary to maximize its diagnostic performance 
for unknown primary malignancies and optimize the 
management of these patients. 
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